Morning Briefing
Summaries of health policy coverage from major news organizations
Johnson & Johnson Deal May Bring HIV/AIDS Drugs To Developing Countries Faster
Johnson & Johnson's Tibotec Pharmaceuticals unit on Thursday announced it granted multiple licenses to generic drug manufacturers" to provide copies of [the experimental HIV/AIDS drug rilpivirine hydrochloride] TMC278 in sub-Saharan Africa, India and parts of Asia if it's approved by regulators," Bloomberg Businessweek reports.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
